Rheumatoid arthritis and response to anti-TNF alpha therapy: blood
Summary:
Analysis of whole blood from rheumatoid arthritis patients at baseline of infliximab therapy. Infliximab is an anti-TNF alpha antibody. Clinical response to infliximab determined at week 14 of therapy. Results identify a gene expression signature for predicting the response to infliximab.
Julià A, Erra A, Palacio C, Tomas C et al. An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis. PLoS One 2009 Oct 22;4(10):e7556. PMID: 19847310